Cyclophosphamide

Acute Coryza, Retinoblastoma, Lymphoma, Large B-Cell, Diffuse + 20 more

Treatment

41 FDA approvals

20 Active Studies for Cyclophosphamide

What is Cyclophosphamide

Cyclophosphamide

The Generic name of this drug

Treatment Summary

Cyclophosphamide is a medication used to treat cancer, including lymphoma and leukemia. It must be processed in the liver to become an active form of chemotherapy. Side effects of the drug include hair loss, infertility, birth defects, and an increased risk of cancer. It is also used to shear sheep.

Cyclophosphamide

is the brand name

image of different drug pills on a surface

Cyclophosphamide Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cyclophosphamide

Cyclophosphamide

1959

75

Approved as Treatment by the FDA

Cyclophosphamide, otherwise called Cyclophosphamide, is approved by the FDA for 41 uses like Retinoblastoma and Lung Cancers .

Retinoblastoma

Lung Cancers

Glomerulonephritis

Non-Hodgkin's Lymphoma (NHL)

Adenocarcinoma of the Ovaries

Acute monocytic leukemia

histiocytic lymphoma

Hodgkins Disease (HD)

Acute Myeloid Leukemia (AML)

Breast Cancer

Multiple Myeloma (MM)

Disseminated Neuroblastoma

Nephrotic syndrome with lesion of minimal change glomerulonephritis

Chronic Myeloid Leukemia (CML)

Leukemia, Myelocytic, Acute

Burkitt Lymphoma (BL)

Lymphocytic Lymphomas

mixed-cell type lymphoma

Acute Lymphoblastic Leukemia (ALL)

Malignant Lymphomas

Chronic Lymphocytic Leukemia (CLL)

Hodgkin Disease

failure with corticosteroid therapy

Lung Cancer

Acute Myeloid Leukemia

Acute Coryza

Erythema Induratum

Neuroblastoma

Lymphoma, Non-Hodgkin

Acute Lymphoblastic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell

Leukemia, Myeloid, Acute

Breast Cancer

Non-Hodgkin's Lymphoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Lymphoma, Non-Hodgkin

Adenocarcinoma

Multiple Myeloma

Lymphoma, Large B-Cell, Diffuse

Chronic Lymphocytic Leukemia

Retinoblastoma

Effectiveness

How Cyclophosphamide Affects Patients

Cyclophosphamide is a type of medication used to treat cancer. It works by adding chemicals called alkyl groups to DNA, which prevents the cells from dividing and stops them from growing. It also adds methyl or other alkyl groups to molecules that should not be there, which disrupts how DNA works and causes the cells to die. Alkylating agents are cell cycle-nonspecific, meaning they affect any cell at any stage of its life cycle.

How Cyclophosphamide works in the body

Alkylating agents are drugs that prevent cancer cells from reproducing by damaging their DNA. They do this in three ways: by attaching alkyl molecules to the DNA, creating bonds between the atoms of the DNA, and causing the nucleotides to mispair. As a result of this damage, the DNA is unable to be copied, preventing further cancer cell growth.

When to interrupt dosage

The advised dosage of Cyclophosphamide is contingent upon the diagnosed condition, for example Lymphoma, Glomerulonephritis and Leukemia, Myelocytic, Acute. The measure of dosage varies depending on the administration technique (e.g. Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular or Powder, for solution - Intravenous) featured in the table below.

Condition

Dosage

Administration

Breast Cancer

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Leukemia, Lymphocytic, Chronic, B-Cell

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Hodgkin Disease

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Retinoblastoma

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lymphoma, Large B-Cell, Diffuse

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lymphoma, Non-Hodgkin

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Acute Myeloid Leukemia

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Acute Lymphoblastic Leukemia

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lung Cancer

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

failure with corticosteroid therapy

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lymphoma, Non-Hodgkin

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Chronic Lymphocytic Leukemia

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Multiple Sclerosis

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Erythema Induratum

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Glomerulonephritis

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Acute Coryza

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Lupus

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Leukemia, Myeloid, Acute

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Neuroblastoma

, 25.0 mg, 50.0 mg, 200.0 mg, 500.0 mg, 1000.0 mg, 2000.0 mg, 100.0 mg/mL, 20.0 mg/mL, 50.0 mg/mL, 200.0 mg/mL, 1000.0 mg/mL, 500.0 mg/mL

Oral, Tablet - Oral, Tablet, , Capsule, Capsule - Oral, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Parenteral, Powder, for solution - Parenteral, Injection, powder, for solution - Intravenous; Oral, Injection, powder, for solution, Intravenous; Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous; Oral, Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, powder, for solution - Intramuscular; Intraperitoneal; Intrapleural; Intravascular, Injection, solution - Intravenous, Injection, solution, Injection, Concentrate, Concentrate - Intravenous, Injection - Intravenous

Warnings

Cyclophosphamide Contraindications

Condition

Risk Level

Notes

severely depressed bone marrow function

Do Not Combine

Urinary Bladder Neck Obstruction

Do Not Combine

There are 20 known major drug interactions with Cyclophosphamide.

Common Cyclophosphamide Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Cyclophosphamide.

Abetimus

Major

The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Abetimus.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Cyclophosphamide.

Cyclophosphamide Toxicity & Overdose Risk

Common side effects of taking this drug include lowered white blood cell count, fever, hair loss, nausea, vomiting, and diarrhea.

image of a doctor in a lab doing drug, clinical research

Cyclophosphamide Novel Uses: Which Conditions Have a Clinical Trial Featuring Cyclophosphamide?

1165 active clinical trials are currently being conducted to examine the potential of Cyclophosphamide to treat Breast Cancer, Lymphocytic Lymphomas and Multiple Myeloma.

Condition

Clinical Trials

Trial Phases

Acute Myeloid Leukemia

267 Actively Recruiting

Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1

Multiple Sclerosis

127 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Hodgkin Disease

3 Actively Recruiting

Not Applicable, Phase 1

Multiple Myeloma

6 Actively Recruiting

Phase 1, Phase 2

Lung Cancer

168 Actively Recruiting

Phase 1, Not Applicable, Phase 3, Phase 2, Early Phase 1

Lymphoma, Large B-Cell, Diffuse

0 Actively Recruiting

Chronic Lymphocytic Leukemia

142 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Adenocarcinoma

2 Actively Recruiting

Phase 2, Phase 1

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

0 Actively Recruiting

Neuroblastoma

0 Actively Recruiting

Glomerulonephritis

1 Actively Recruiting

Phase 3

Leukemia, Myeloid, Acute

0 Actively Recruiting

Erythema Induratum

0 Actively Recruiting

failure with corticosteroid therapy

0 Actively Recruiting

Retinoblastoma

5 Actively Recruiting

Phase 2, Phase 1

Lymphoma, Non-Hodgkin

1 Actively Recruiting

Phase 1

Breast Cancer

21 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Lupus

9 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1

Cyclophosphamide Reviews: What are patients saying about Cyclophosphamide?

5

Patient Review

9/13/2010

Cyclophosphamide for Scleroderma Lung Disease

I've been on this medication for a short time, so it's hard to say if it's effective yet. I have noticed some hair loss and decreased appetite. When I do eat, I sometimes feel nauseous. It seems like my breathing is better, but the change has been very gradual.

4.7

Patient Review

3/15/2011

Cyclophosphamide for Cancer of the Ovary

This medicine has been incredibly effective, moreso than I could have hoped. My doctors decided to try something new on my 8th battle with cancer, and I'm so glad they did. As a college student, it's important to me that I can still go to school and work while taking this medication. The nausea has been tough to deal with but it's better than chemotherapy by far.

4.7

Patient Review

5/26/2008

Cyclophosphamide for Breast Cancer that has Spread to Another Part of the Body

4.3

Patient Review

9/1/2012

Cyclophosphamide for Scleroderma Lung Disease

I took this medication to get my Lupus under control, and it was successful. However, I experienced some troubling side effects afterwards that required me to take another medication. Thankfully, my liver returned to normal a few months later.

4

Patient Review

8/1/2008

Cyclophosphamide for Multiple Myeloma

3.7

Patient Review

10/13/2010

Cyclophosphamide for Malignant Tumor of the Kidney

I've been on this drug for over two years now and have had no significant side effects. My PFTs (not sure what this stands for) were stable when I switched to this medication, and I take 5mg of prednisone daily as well.

3.3

Patient Review

5/12/2009

Cyclophosphamide for Nephrotic Syndrome

I experienced few side effects with this drug, which is great compared to many other drugs I've tried. The only downside is that it didn't completely solve my hair loss issue, but it did help somewhat.

3

Patient Review

2/4/2014

Cyclophosphamide for Acute Monocytic Leukemia

I experienced a lot of abdominal pain, pelvic pain, cramps, burning, and watery stools while on this medication. I also had anal pressure and pain, gas, bloating, and a frequent urge to defecate. As a result of all these side effects, I lost weight and my appetite completely vanished. I have been off the medication for almost two months now and I still haven't had a normal stool.

3

Patient Review

7/23/2009

Cyclophosphamide for Scleroderma Lung Disease

My father had to be taken off this drug due to mental side effects. He was also taking dexamethasone, which may have contributed to the confusion and delusions he experienced.

2.7

Patient Review

10/26/2007

Cyclophosphamide for Breast Cancer that has Spread to Another Part of the Body

2.7

Patient Review

2/18/2009

Cyclophosphamide for Cancer of the Ovary

2

Patient Review

4/30/2012

Cyclophosphamide for Systemic Lupus Erythematosus

I started this medication after my OC recurred. So far, I'm liking it because I haven't experienced any hair loss or severe nausea.

1

Patient Review

1/14/2013

Cyclophosphamide for Cancer of the Ovary

I have now been on Cellcept twice, and can attest to its ineffectiveness. Not only does it lower your immunity to the point where you become susceptible to infection, but it also doesn't do anything to prevent the Scleroderma from coming back.

1

Patient Review

3/15/2009

Cyclophosphamide for Acute Monocytic Leukemia

I have recently been placed on this medication, but I haven't taken it for long enough to know if it's effective.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cyclophosphamide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is cyclophosphamide a chemo or immunotherapy?

"Cyclophosphamide is an alkylating chemotherapeutic agent that suppresses the immune system."

Answered by AI

What is the cyclophosphamide used for?

"Cyclophosphamide is a medication used to treat cancer in various parts of the body, including the ovaries, breast, blood and lymph system, nerves, and eyes. It is also used for treating multiple myeloma and skin tumors."

Answered by AI

Is cyclophosphamide a steroid?

"Cyclophosphamide is sometimes called a "steroid-sparing agent" because it has different side effects than prednisone."

Answered by AI

How cyclophosphamide is given?

"This medication can be administered in various ways depending on the diagnosis, including intravenously, orally in tablet form, or by injection into a muscle, the abdominal lining, or the lining of the lung."

Answered by AI

Clinical Trials for Cyclophosphamide

Image of University of Iowa in Iowa City, United States.

Lung Cancer Screening for Lung Cancer

50 - 77
All Sexes
Iowa City, IA

The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose CT for adults aged 50-80 with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years. Despite insurance coverage, only 17% of eligible Iowans were screened in 2024. Barriers include the complexity of screening and competing demands in primary care. To address these challenges, investigators propose a two-part intervention: a blood-based screening test to simplify LCS and a community pharmacist-led referral program integrated into routine pharmacy care. Eligible patients will be identified at Greenwood Pharmacy in Waterloo, Iowa. Interested individuals will be consented by a pharmacist and engaged in shared decision-making about LCS. Participants may decline screening, complete the DELFI Diagnostics FirstLook lung cancer screening blood test, or pursue CT screening through their primary care physician. Those choosing the blood test will be referred to Cedar Valley Family Medicine. Patients with a positive result will complete a standard shared decision-making visit with their PCP and, if appropriate, undergo confirmatory CT imaging. Patients with a negative result will enter a screening cohort and be re-screened annually for an additional year.

Waitlist Available
Has No Placebo

University of Iowa (+2 Sites)

Jill Kolesar, PharmD, MS, FCCP

Eli Lilly and Company

Image of National Institutes of Health Clinical Center in Bethesda, United States.

TSLPR-CART for Acute Lymphoblastic Leukemia

18 - 120
All Sexes
Bethesda, MD

Background: * gPhiladelphia (Ph)-like h acute lymphoblastic leukemia (ALL) is a high-risk subgroup of B-ALL associated with high rates of chemotherapy resistance and relapse. Ph-like ALL is defined by an activated cytokine receptor and kinase signaling profile similar to that of Philadelphia chromosome-positive (Ph+) ALL yet lacking BCR-ABL1 rearrangement. * Approximately half of childhood and adult Ph-like ALL cases have rearrangement in cytokine receptor like factor-2 (CRLF2), which encodes one subunit of the thymic stromal lymphopoietin receptor (TSLPR) and heterodimerizes with the interleukin-7 receptor alpha (IL7Ra) subunit. Its ligand, TSLP, is a cytokine that plays a critical role in regulation of the immune response and in the differentiation of hematopoietic cells. TSLP binding to the TSLPR in B-ALL induces constitutive Janus kinases and signal transducers and activators of transcription (JAK/STAT) pathway signaling. * Most CRLF2-rearranged (CRLF2-R) Ph-like ALL cases can be readily identified by increased TSLPR surface expression by flow cytometric immunophenotyping, and specific CRLF2 rearrangements can then be confirmed by genetic testing. Given the prevalence of CRLF2 rearrangements and the poor clinical outcomes of patients with Ph-like ALL, TSLPR is a promising target for new immunotherapies. * Chimeric antigen receptor-expressing T cells (CAR) have proven highly successful in patients with cancer with dramatic responses in \>70% of patients with relapsed/refractory B-ALL treated with CD19-redirected CAR T cells, resulting in Food and Drug Administration (FDA) approval of a CD19 CAR T-cell immunotherapy in children and young adults. A trial of CAR T cells targeting CD22 is currently ongoing at the NCI and has demonstrated comparable efficacy and toxicity results as the CD19 CAR. * Emerging data have indicated that not all patients respond, and up to 50% of those who achieve remission will subsequently relapse. The most common cause of relapse is the target antigen loss, which is likely multi-factorial in etiology and for which this mechanism of escape is under active investigation. Novel targets are needed. * This will be the first in human testing of anti-CRLF2-R/TSLPR CAR T cell (TSLPRCART) adoptive cell therapy. Objective: -To assess the safety of administering escalating doses of autologous anti-CRLF2-R/TSLPR-CAR engineered T cells (TSLPR-CART) containing a truncated epidermal growth factor (tEGFR) suicide switch to determine a maximum tolerated dose (MTD) in participants with recurrent or refractory CRLF2/TSLPR-overexpressing B-cell acute lymphoblastic leukemia (ALL) following a cyclophosphamide/fludarabine lymphodepletion regimen. Eligibility: * Age \>= 18 years * Participants must have confirmed diagnosis of a B-cell ALL with TSLPR+ expression on flow cytometry who have relapsed or refractory disease after at least one standard chemotherapy regimen and one salvage regimen, with no alternative curative options. Design: * This is a first-in-human Phase I trial aimed to determine the safety of TSLPR-CART in participants with recurrent or refractory B-cell ALL. * Participants will undergo apheresis and TSLPR-CART will be manufactured from the enriched T-cell product * Participants will receive LD preparative regimen of fludarabine and cyclophosphamide followed by an infusion of TSLPR-CART. * The MTD of autologous TSLPR-CAR T cells using a 3 + 3 dose escalation design will be determined. Additional participants in an expansion cohort will be treated at an MTD dose to evaluate the rate of response to TSLPR-CAR T cells. Participants will be evaluated for toxicity, anti-tumor response, CAR expansion and persistence, and other biologic correlatives....

Phase 1
Waitlist Available

National Institutes of Health Clinical Center

Nirali N Shah, M.D.

Have you considered Cyclophosphamide clinical trials?

We made a collection of clinical trials featuring Cyclophosphamide, we think they might fit your search criteria.
Go to Trials
Image of University of Arizona Mel and Enid Zuckerman College of Public Health in Tucson, United States.

Social Support Training for Lung Cancer Survivors

18 - 99
All Sexes
Tucson, AZ

This study tests whether clinical interventions to optimize support receptivity lead to improvements in social integration and quality of life (QOL) amongst long-term lung cancer survivors. The feasibility and acceptability of the intervention and assessment procedures will be examined. Thirty long-term lung cancer survivors will be randomized to a support receptivity intervention or an attention-control condition. Our intervention draws on cognitive behavioral therapy (CBT) strategies to reduce social anxiety, improve social awareness, and promote social integration. We will use two novel in vivo sampling methods using a mobile phone platform to assess social engagement and QOL improvements: 1) recording via the Electronically Activated Recorder to capture daily social interactions, and 2) repeated self-report sampling where participants answer questions about their social engagement experiences via their personal cell phone.

Waitlist Available
Has No Placebo

University of Arizona Mel and Enid Zuckerman College of Public Health

Scott Carvajal, PhD, MPH

Image of Foothills Medical Centre in Calgary, Canada.

Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis

18 - 65
All Sexes
Calgary, Canada

Canada has one of the highest rates of multiple sclerosis (MS). MS patients experience disabling motor, visual, and sensory symptoms, and a high risk of comorbid major depressive disorder (MDD) and severe fatigue. The lifetime prevalence of MDD in MS patients is about 50%, and nearly 90% experience severe fatigue, both of which are not responsive to typical treatments. Repetitive transcranial magnetic stimulation (rTMS) is a first line, Health Canada approved non-invasive neurostimulation treatment for MDD. rTMS induces electrical activity in the cortex using magnetic fields generated outside of the head to drive neuronal firing in the target site. However, MS is typically an exclusion criterion due to safety concerns. The goal of this clinical trial is to learn if repeated transcranial magnetic stimulation (rTMS) can be used to treat depression symptoms in adults with multiple sclerosis (MS). rTMS is a non-invasive form of brain stimulation that uses magnetic pulses to stimulate specific parts of the brain. The main questions it aims to answer are: Is rTMS safe, tolerable, and feasible to deliver as a treatment for depression and fatigue symptoms in individuals with MS? Does rTMS show preliminary effectiveness in improving depression and fatigue symptoms in this population? Researchers will determine whether rTMS treatment improves mood, fatigue, and cognition across time points (baseline, after treatment, and 4-week follow-up). Participants will: Complete screening, questionnaires, clinical assessments, cognitive tests, a brain MRI to help tailor the TMS treatment, and receive daily TMS sessions for 5 consecutive days, including: Pre-TMS brain mapping, five rTMS treatments (3 minutes) per day, separated by one hour. A safety and tolerability questionnaire will be administered daily. Complete post-treatment assessments (questionnaires, cognitive tests, psychiatric evaluation). Complete a 4-week follow-up visit, in person or virtually. Wear a fitness tracking watch during the study so researchers can collect activity data remotely. About 20 people will take part in this study through the University of Calgary.

Phase 1
Waitlist Available

Foothills Medical Centre

Adrianna Giuffre, PhD.

Image of Ohio State University Comprehensive Cancer Center in Columbus, United States.

Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia

18+
All Sexes
Columbus, OH

This phase II trial tests how well nemtabrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as CLL or SLL at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Giving nemtabrutinib in combination with venetoclax may kill more cancer cells in patients with CLL or SLL.

Phase 2
Waitlist Available

Ohio State University Comprehensive Cancer Center

Jennifer A Woyach, MD

Merck Sharp & Dohme LLC

Have you considered Cyclophosphamide clinical trials?

We made a collection of clinical trials featuring Cyclophosphamide, we think they might fit your search criteria.
Go to Trials
Image of OHSU Knight Cancer Institute in Portland, United States.

Ruxolitinib + Azacitidine for Acute Myeloid Leukemia

18+
All Sexes
Portland, OR

This phase I trial studies the side effects and best dose of ruxolitinib (Rux) therapy alone (monotherapy) followed by Rux plus azacitidine (AZA) maintenance therapy and to see how well it works in treating patients with acute myeloid leukemia (AML) who are undergoing reduced intensity allogeneic hematopoietic stem cell transplantation (alloHSCT). AlloHSCT provides the only chance for cure for many patients with AML. AlloHSCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. This is often a sister or brother, but could be an unrelated donor. One of the common reasons for death after an alloHSCT is graft versus host disease (GVHD), which occurs when the transplanted cells from the donor attacks the recipient's normal cells. Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat GVHD by blocking the signals of the cells that cause GVHD. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. Giving Rux after the transplant may stop GVHD from occurring. Maintenance therapy with AZA, may help prevent or delay cancer from coming back. Giving Rux monotherapy followed by Rux plus AZA maintenance therapy may be safe, tolerable, and/or effective in treating patients with AML who are undergoing alloHSCT.

Phase 1
Waitlist Available

OHSU Knight Cancer Institute

Jennifer N Saultz

Incyte Corporation

Image of Fairfield Univesity Nursing School in Fairfield, United States.

Treatment for Multiple Sclerosis

18+
All Sexes
Fairfield, CT

This study compared two educational methods. Participants were assigned to participate in a 360-degree experience or a slideshow presentation. The 360-degree video group included a brain and MS program. The comparison group was given a slideshow presentation with the same information. Participants viewed the 360-degree program or the slideshow presentation only once. The online-based materials consisted of a demographic form (age, gender, race and ethnicity, and name of school), knowledge questionnaires, and an experiential learning scale. Pre-intervention, participants were asked about demographic information, whether they had previous experience with MS, the science classes they completed in high school and college, and their knowledge of the human brain and MS pathophysiology. At both pre- and post-intervention, participants completed the Multiple Sclerosis Magnetic Resonance Imaging Knowledge Questionnaire (MSMRIKQ) and the Multiple Sclerosis Knowledge Questionnaire (MSKQ). At post-intervention, participants completed a lesson experiential questionnaire about their experience viewing either the 360-degree video or the slideshow presentation. Permission to use the three instruments was obtained from their respective copyright holders.

Waitlist Available
Has No Placebo

Fairfield Univesity Nursing School (+1 Sites)

Image of CancerCare Manitoba in Winnipeg, Canada.

Levofloxacin for Blood Cancers

18+
All Sexes
Winnipeg, Canada

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Patients with MDS and AML commonly experience complications related to infection, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of levofloxacin (antibiotic) in MDS and AML patients to safely reduce the risk of infection. In this study 50% of patients will be randomized (like a flip of a coin) to receive levofloxacin and the other 50% will receive usual care (control). The primary objective of the trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. Additionally, the investigators will monitor both groups of patients to see if the investigators improve the risk and/or severity of infection. Levofloxacin is commonly used in other clinical settings but has not been studied in patients with MDS or AML receiving outpatient chemotherapy (ie, chemotherapy that can be given from clinic, rather than a hospital).

Phase 2
Waitlist Available

CancerCare Manitoba

Have you considered Cyclophosphamide clinical trials?

We made a collection of clinical trials featuring Cyclophosphamide, we think they might fit your search criteria.
Go to Trials